– USA, CT – Osmol Therapeutics, a biopharmaceutical company focused on developing a treatment to prevent chemotherapy-induced peripheral neuropathy, today announced the appointment of Teresa Bitetti to its Board of Directors.
“Teresa Bitetti has over 20 years of experience in developing and commercializing oncology products, including global responsibility for oncology business activities. Bitetti’s experience will be enormously helpful to Osmol as we advance our lead product, OSM-0205, in the clinic and ultimately prepare for a commercial launch. She is highly regarded for her record in commercializing oncology drugs such as Opdivo, as well as for her strategic vision and global team-building capabilities. On behalf of all of us at Osmol, I welcome Teresa to the Board of Directors,” said CEO, Bob Linke.
About Teresa Bitetti
Teresa Bitetti is currently President of the Global Oncology Business Unit at Takeda Pharmaceutical Company Ltd. She is responsible for oncology business activities around the world, overseeing a global portfolio consisting of therapies in hematological malignancies and lung cancer. Before joining Takeda in April 2019, Teresa held a series of increasingly senior positions over 18 years at Bristol-Myers Squibb, culminating in her appointment as SVP of Worldwide Oncology Commercialization.
“Osmol is developing a therapy to prevent chemotherapy-induced peripheral neuropathy, a painful and often debilitating off-target toxicity associated with the use of taxanes,” said Teresa Bitetti. “CIPN disproportionately affects women because taxanes remain a mainstay in the treatment of breast cancer. With no FDA-approved treatment for CIPN, there is a tremendous need for a therapy that can prevent this debilitating side-effect and improve the quality of life for patients. I look forward to working with the team at Osmol to bring OSM-0205 to cancer patients.”
Teresa Bitetti has a Master in Business Administration degree from the University of Virginia Darden School of Business and a Bachelor of Arts in Classical Civilization from Wellesley College.
About Osmol Therapeutics
Osmol Therapeutics is a privately held biopharma company focused on developing a treatment to prevent chemotherapy-induced peripheral neuropathy based on the ground-breaking work of Dr. Barbara Ehrlich. The company’s lead indication will be for the prevention of CIPN related to taxane treatment. As an example of the extent of this condition, up to 80% of taxane-treated patients with breast cancer have been reported to experience CIPN.
For more information: https://osmoltherapeutics.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.